Fig. 3

PANC1, BxPC3, and AsPC1 cells induce anti-tumoral or pro-tumoral state of innate immune cells. (A) The relative expression of TNF-?, IL-12, and IL-10 in coro1a: GFP⁺ cells sorted from PANC1, BxPC3, and AsPC1 xenografts (* p < 0.05, t test). (B) Representative confocal images of innate immune cells in PANC1, BxPC3, and AsPC1 xenografts at 4 dpi after treatment with DMSO (control) or LPS (150 ?g/mL). (C) Qualification of coro1a: GFP⁺ innate immune cell percentage in PANC1, BxPC3, and AsPC1 cells at 4 dpi under the control and LPS condition (no. of innate immune cells/no. of tumor cells × 100). Results are shown as means ± SEM from nine different individuals (** p < 0.01, t test). (D) Enlarged confocal images of innate immune cells co-localized with PANC1 and AsPC1 cells at 4 dpi under the control or LPS treatment. Arrowheads point to the co-localized cells. (E) Representative confocal images of PANC1, BxPC3, and AsPC1 xenografts at 1 dpi and 4 dpi with the treatment of DMSO (control) or LPS (150 ?g/mL) respectively. (F) Relative tumor growth in xenografts (4 dpi vs. 1 dpi) after being treated with DMSO or LPS. Results are from nine different individuals (* p < 0.05, ** p < 0.01, *** p < 0.001, t test). dpi, days post injection. Scale bars in (B,E), 50 µm; in (D), 25 µm.